Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept 25 mg Twice Weekly in Moderate to Severe Persistent Asthma
2004-003778-27Phase 2Completed
- Sponsor
- Wyeth
- Start
- Feb 2005
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Etanercept 25 mg twice weekly with Placebo twice weekly (2 arms). Primary endpoint: Change in FEV1 % predicted from baseline to week 12. Started Feb 2005; status: completed.
02
Drugs
etanercept
03
Conditions
asthma
Beyond the preview
Go deeper on 2004-003778-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003778-27.